Finally, Kumagai et al. recently showed that PD-1 expression balance between effector and regulatory T cells in the TME predicts the clinical efficacy of PD-1 blockade therapies and is superior to PD-L1 expression or TMB in patient cohorts with NSCLC, gastric cancer, or malignant melanoma [116]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.